Furthermore, studies in a rat model of CKD have shown that administration of a FGFR4-specific blocking antibody (anti-FGFR4) not only prevents the induction of cardiac hypertrophy (155), but also blocks the progression of cardiac injury in animals with already established cardiac hypertrophy (164). Here, FGFR4 is linked to chronic kidney disease.